Saturday, September 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 30, 2026

FSD's Big Week, Greg Abel Makes a Mark on Berkshire Hathaway, and 24/7 Trading

View original at finance.yahoo.com
FSD's Big Week, Greg Abel Makes a Mark on Berkshire Hathaway, and 24/7 Trading In this podcast, Motley Fool contributors Travis Hoium, Lou Whiteman, and Jon Quast discuss: Full self-driving (FSD) is here...kind of…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 8-9 accidents reported with vehicles during safety driver testing

    80% confidence
  • Expect AI data centers in space in the next three years

    80% confidence
  • Markets need volume for price discovery

    80% confidence
  • We're headed toward the tokenization of all assets

    80% confidence
  • People don't know what they want until you show it to them

    80% confidence
  • Take what he says very seriously, but don't necessarily take the timetable seriously

    80% confidence

Data points we hold from this source

The Walt Disney Company · market cap200-230 billion_USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com